ArticleCancer biology & therapy2007

Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer.

Kiranmayi Tadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.